Shares of Insmed jumped on Thursday after Bloomberg News reported that French drugmaker Sanofi is weighing an acquisition of the U.S. company. The stock traded at $144.17 at 2:15 p.m. Eastern time, up $24.37, or 20.3%, from Wednesday’s close of $119.80. It climbed as high as $148.94 shortly after 10 a.m., when the shares first surged.
Bloomberg, citing people familiar with the matter, said Sanofi is speaking with advisers as it studies a possible deal, according to Reuters. Deliberations are ongoing and any deal could still be weeks away, the report said. No deal has been announced. Sanofi said it does not comment on market rumors, and Insmed did not immediately respond to a Reuters request for comment.
Insmed, based in Bridgewater, New Jersey, sells Brinsupri, a treatment for non-cystic fibrosis bronchiectasis, a chronic lung disease, and Arikayce, another lung treatment. On Oct. 29 it reported third-quarter revenue of $524.4 million, including $400.1 million from Brinsupri, and raised its 2026 Brinsupri sales forecast to $1.35 billion to $1.4 billion.
…
That’s the story. … Thank you for listening to Cedar Global Markets. We’re supported by our partners, and you can learn more about the partner featured on this page. We’ll see you next time.




